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Summary 
 
In tumors and in several diseases tissues are characterized by healthy and diseased cells, creating 
mosaicism. Currently, the mosaicism phenomenon is hard to understand and reproduce in vivo.  
A possible strategy is the generation of conditional and inducible mutations by crossing a floxed 
mouse with a transgenic animal carrying Cre recombinase. This model can be studied in different 
conditions, to analyze the mechanisms at the base of development, cellular homeostasis, and tumor 
progression.  
At the present days, mosaicism’s studies are affected by the lack of a tool that reproduces the in vivo 
mosaicism allowing to examine phenomenon in its entirety, without the need to cross many different 
transgenic animals. 
The tool proposed can satisfy these conditions, by allowing the creation and detection of a conditional 
genetic knock-out mosaicism with Cre recombinase activity.  
Cre recombinase realizes a homologous recombination on a DNA sequence flanked by two Lox sites. 
Depending on the DNA sequence, if it is a target gene or a STOP site situated in the 5’ portion of a 
gene, the target gene can be repressed or activated respectively.  
Importantly, the generation and control of a mosaic allows to understand not only mosaicism, but the 
cell-autonomous effect of a mutation. Therefore, it is possible to understand, separately, the 
contribution of environment and genome on the cell fate. 
The tool we devised is formed by a plasmid including the genes of two different fluorescent proteins 
(a GFP and a RFP) assembled in such a way that only one of the two genes is expressed. In its native 
form, the plasmid, called Beatrix, expressed the RFP but upon homologous recombination mediated 
by the enzyme Cre, the expression switches to the GFP. Therefore, this sensor signals with a color 
shift the presence and activity of Cre. When this sensor is transduced in a conditional mutant mouse, 
the color shift signals the mutation. 
Furthermore, the plasmid presents a DNA sequence coding Cre recombinase. Its expression is 
achieved only after the complete plasmid recombination, inducing the amplification of Cre activity. 
In a floxed animal, the induction of mosaicism is possible with a low level of Cre activity that can be 
regulated spatially and temporally. In our tool, the induction of mosaicism occurs thanks to the 
inducer, a plasmid that expresses an inducible Cre recombinase. The inducible Cre is fused with 
Ligand Binding Domains (LBDs) that define its cytoplasmic localization. Following the 
administration of a chemical drug, such as Tamoxifen (4OHT), the inducible Cre changes in the 
intracellular localization associated to the nuclear localization. In the nucleus, inducible Cre 
recombines floxed DNA sequences (among which our sensor) on plasmids and genome. 
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Indeed, the temporal window of Cre activity can be defined by administering Tamoxifen.  
However, the only presence of the receptor domain it is not sufficient to obtain the complete 
cytoplasmic localization, inducing a background Cre activity without the administration of 
Tamoxifen (leakage). Moreover, due to the presence of Cre recombinase in our construct, the leakage 
of inducible Cre is increased, inducing recombination in temporal windows not defined by operators. 
So, the system is not reliable at 100%.   
To solve this problem, the system has been modified with the fusion of a destabilized domain (DD), 
that induces the protein degradation by proteasome 26S, and the removal of the PolyA, that induces 
the mRNA destabilization. 
In presence of Trimethoprim, DD is stabilized, preventing the protein degradation.   
 
In this thesis are proposed several versions of inducible Cre recombinase to define which one has the 
smallest leakage, so the optimal version for the tool. We transfected the constructs in different cell 
cultures (HEK293T, NIH, Mouse fibroblast primary cell) through both chemical (Effectene and 
Lipofectamine) and physical methods (Electroporation).  
The acquisition of the cell cultures was performed by means of two-photon microscopy and the 
images have been analyzed on the fluorescence with specific software. 
After the generation of the optimal system to create a genetic mosaicism in cell cultures, the next step 
is the in vivo application on floxed animals to reproduce and study genetic inactivated mosaicism on 
whole organism.  
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INTRODUCTION 
1.  Mosaicism 
 
All multicellular organisms have different cell types with the same genome. The differences of every 
cell types depend on the different genetic expression that induces different functionalities. 
Some tissues could present the same type cells with two alternative genotypes, one leading to a 
mutated phenotype. This phenomenon is called mosaicism.  
Mosaicism can result from various mechanisms, including chromosome non-disjunction, anaphase 
lag and endoreplication. Anaphase lagging appears to be the main process by which mosaicism arises 
in the preimplantation embryo. Mosaicism may also results from a sequence mutation during 
development or life, which is propagated to only a subset of the adult cells. 
Different types of mosaicism exist: somatic and germline. 
Germline mosaicism is a type of genetic mosaicism where more than one set of genetic information 
is found specifically within the gamete cells. 
Somatic mosaicism refers to the occurrence of two genetically distinct populations of cells within an 
individual, derived from a postzygotic mutation. It may affect only a portion of the body and are not 
transmitted to progeny [1], [2].  
The mutations can be chromosomal, genetic and mitochondrial, that are changes most often brought 
on by problems that occur during meiosis or by mutagens (chemical, radiation, endogenous 
processes). 
Chromosomal mutations can result in changes in the number of chromosomes in a cell or changes in 
the structure of a chromosome. There are several types of chromosomal mutations: deletion, 
duplication, translocation, inversion of chromosome segments, or duplication and deletion of whole 
chromosome, such as trisomy and monosomy. The phenotypic consequences of these events vary 
considerably based on the size of the event and the genomic region involved. 
Genetic mutations can result in changes in the DNA sequence and it is possible in different ways: 
substitution (silent, missense, nonsense mutations), insertion and deletion mutations. 
Mitochondrial mutations can result in changes in the mitochondrial DNA (mtDNa). The rate of 
mutation of mtDNA is tenfold than for nuclear DNA because of the absence of reparation systems. 
In biological system, mosaicism can show positive or negative effects. Negative effects are associated 
to particular diseases, in which there is the contemporary presence of healthy and diseased cells in 
the same tissue.   
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An example of diseases with mosaicism are the X-linked diseases in the female eukaryotic mammals. 
Certain type of X-linked disorders, such as Rett Syndrome, are usually lethal during embryogenesis 
in hemizygous male because of the presence of only one mutated gene in X chromosome, so all cells 
are mutated. Live born individuals are usually female for the presence of two gene for the two X 
chromosomes, one wild-type and one mutated.  
The inactivation of X chromosome by Barr’s body characterizes all cells of a female to normalize the 
relative levels of gene expression from the sex chromosome. This normalization is achieved by 
epigenetic silencing of most of the genes on one of the two X chromosomes.  
X chromosome inactivation is initiated during the development and the choice between maternal and 
paternal X chromosomes appears to be random. The intrachromosomal spreading of inactivation is 
controlled by a large noncoding RNA, Xist, which is transcribed from the X chromosome itself. Xist  
associates in cis with the inactive X chromosome. The inactive chromosome is characterized by 
increased DNA methylation and repressive histone modification [3]. 
Therefore, the X-chromosomal inactivation defines mosaicism in the female and when there is a 
mutated gene, some cells are healthy and the remaining are diseased. 
Another example of mosaicism is cancer, which is the result of consecutives somatic mutations.  
Cancer is a disease of genetic mosaicism because cancerous cells present genetic mutations that are 
absent in normal cells within the same individual. Theodor Boveri observed it in 1922 on a neoplasia 
for the first time. Therefore, the cancer tissue presents some healthy and diseased cells. 
At the level of the whole organism, appreciation of the mosaic phenotype depends on tissue-to-tissue 
genetic variation.   
The possibility to replicate mosaicism-based pathologies and cell autonomous effects of a mutation 
in vivo animal would be very important for many researches, to understand and define the alterations 
induced by genome or environment. 
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Figure 1: Different cells in a mosaicism model (top) and a single cell surrounded by cells with different genotype (bottom).  
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2.  Cre/Lox system 
 
In the last decade, several gene editing system emerged and their use in different fields has became 
widespread. 
Gene editing is achieved through different molecular systems, like TALENs, CRISPR Cas9, Flp and 
Cre recombinase. 
In particular, Flp and Cre recombinase are tyrosine kinases of the λ integrase family that catalyze the 
cutting and rejoining of two different DNA segments at specific sequences (site-specific 
recombination).  
Cre recombinase, isolated from bacteriophage P1, is an enzyme composed by 343 amino acids (aa) 
with two basic domains: the N-terminal binding domain and the C-terminal catalytic domain.  
In the bacteriophage, P1 Cre has two roles. First, Cre ensures that the 100-kb cyclically permuted and 
linear redundant genome is circularized after infection into E.coli. The host homologous 
recombination system can do it, but when this system fail, Cre can efficiently circularize the infecting 
DNA. Second, Cre ensures maintenance of the P1 DNA in lysogenesis. The bacteriophage P1 genome 
resides primarily as a unit copy plasmid as a lysogen. Homologous recombination can generate dimers 
of the P1 genome after replication. To ensure fidelity in the progeny, the dimers are resolved 
efficiently by Cre providing monomers that are able to properly segregate. 
The enzyme binds site-specific sequences called LoxP (Locus of X-over P1). Lox P sites are 
asymmetric sequences of 34 base pairs (bp), composed by a spacer sequence of 8 bp between two 
inverted repeats of 13 bp (RBE, Recombinase Binding Element) (Figure 3a) [4]. 
The spacer sequence of 8 bp defines the orientation, while each 13 bp palindromic half site is a 
binding site for a Cre monomer. 
In every recombination, four Cre recombinase bind the DNA thanks to protein-protein interactions, 
in which each one binds one of the four palindromic sequences present in the two LoxP sites.  
During the site-specific recombination, the enzyme uses a common mechanism that involves the 
formation of a Holliday junction intermediate (HJ intermediate). The enzyme makes a nucleophilic 
attack using conserved tyrosine sidechains to form covalent 3’ phosphotyrosine linkages. After, the 
5’ OH group can attack the partner substrates to exchange one pair of strands and form a HJ 
intermediate. Isomerization of the HJ intermediate results in activation of the second pair of 
recombinase monomers (Figure 2) [5].  
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Figure 2: Schematic representation of consecutive reactions during Cre recombination: 1) four Cre monomers bind one 
of the four palindromic sequences present in the two LoxP sites. 2) The Tyr (tyrosine) site makes a nucleophilic attack to 
create phosphodiester bond, then 5’ OH attacks the partner substrates (HJ intermediate). 3) Isomerization of the HJ 
intermediate and start of the same reactions in the other substrates. 4) Isomerization of the second HJ intermediate and 
complete recombination. 
 
Therefore, the catalytic event occurs a cleavage, an exchange and a ligation between the two specific-
sites. The cleavage occurs after the first base of the spacer sequence on the top and bottom strands, 
resulting in exchange of six bp between lox sites (Figure 3a-b). 
As in the Figure 3, the LoxP site orientation dictates the DNA rearrangements that can be inversion, 
excision, translocation and insertion of DNA. 
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Figure 3: a) Schematic representation and nucleotide sequence of LoxP site. b) Recombination result after Cre activity, 
in which the two LoxP sites change in the sequence. c) Recombination in cis: intramolecular recombination where, if the 
sites are in a direct (head-to-tail) orientation, will result in the excision; instead, if the site are in opposite (head-to-head) 
orientation, will result in the inversion. d) Recombination in trans: intermolecular recombination where it is possible an 
insertion, deletion/duplication and translocation. 
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Intramolecular recombination, where the sites are in a direct (head-to-tail) orientation, will result in 
the excision of the flanked region between the two sites.  
Instead, inversion is a form of intramolecular recombination where the two LoxP sites are oriented 
as inverted repeats (head-to-head). 
Both events have the reverse reaction that will result in the integration of the segment in 
intermolecular recombination of sites located on two separate DNA molecules, while it will result in 
the reinversion of the segment in intramolecular recombination of sites located on the same DNA 
molecule.  
The Cre/Lox system is commonly used to perform recombination events such as gene knock-outs, 
knock-ins or inversions in eukaryotic systems such as mice, in which a gene or a stop sequence can 
be floxed (included between two identical LoxP sites).  
The recombination on a floxed gene creates a target’s deletion, while the recombination on a floxed 
stop can create a target’s activation (Figure 4) [6].  
 
 
Figure 4: Different applications of Cre/Lox system: A) The exon of a target gene is between two LoxP sites. After 
recombination, the exon excision inducing alteration in the target gene expression. B) Two LoxP sites flank a STOP codon, 
preventing the transgene expression. The recombination defines the excision of STOP codon and the restoration of 
transgene expression. C) Plasmid with an inducible Cre. In normal condition Cre recombinase is inactive, but it is active 
when there is a drug (Tamoxifen, RU 486) that binds the LBD (Ligand Binding Domain).  
 
Several studies have suggested that floxed alleles have differential sensitivities to Cre-mediated 
recombination in genetically identical cell types and in different cell types. The chromosomal location 
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of Lox sites, distances between Lox sites, cell-type-specific epigenetic and the level Cre activity can 
contribute to different recombination in the cells [7].  
The chromosomal location, the distances and cell-type specific epigenetic depend on the gene of 
interest, so every gene has a unique response to Cre recombination. 
Gene recombination can be achieved with complete efficiency by increasing the level of Cre activity 
through the entire cellular complement by the expression of a high level of Cre with an ubiquitous 
promoter. 
 
FLEx Switch 
 
The LoxP is the original site recognized from Cre recombinase, but the enzyme can also recognize 
other sequences. 
These sequences harbor mutations in some nucleotides of LoxP sequence (Figure 5). 
 
 
 
Figure 5: Some different types of Lox sites: the differences are in the spacer sequence.  
 
Even if Cre recombinase tolerates mutated sites, it catalyzes the reaction only between two identical 
Lox sites.  
The FLEx switch is a system, developed by Schnütgen F., et al. (2003) [8], through which the Cre 
activity can be detected with the expression switch of two proteins. In this system, two different genes 
are in opposite orientation, one in sense and one in antisense orientation, thus leading to the expression 
of only the gene in sense. Two different Lox pairs, with alternate organization and a head-to-head 
orientation within each pair of sites, flank the two gene (Figure 6) [8]. 
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Figure 6: FLEx switch: representation of the FLEx switch steps. Two genes are in the opposite orientation and between 
two different pairs of Lox sites (red and black pairs), with alternate organization and a head-to-head orientation within 
each pair of sites. Recombination creates two possible intermediates, which are resolved with a second recombination. In 
the end, there is an inversion of the genes’ orientation, switching the expression. 
 
Initially, the promoter directs the expression of the gene in sense. A recombination can occur between 
a couple of Lox sites (black or red sites in Figure 6) to create one of the two possible intermediates. 
Both intermediates are an inversion of the original construct, with a difference in the position of Lox 
sites pairs. In this intermediate configuration, the intact pairs of Lox sites are in a direct repeat. 
Therefore, a recombination on them results in excision of a DNA segment. This DNA segment is 
between the intact pair of Lox sites, in which there is one of the two Lox sites of the other pair (Figure 
6). 
The final result is the same for both intermediates, with inverted DNA, flanked DNA by only two 
different Lox sites. In this condition, Cre recombinase cannot recombine anymore the plasmid; while, 
if only one Lox pair (in head-to-head orientation) was present, the Cre recombinase would recombine 
the reverse reaction. The two reactions (direct and inverse reaction) occur with the same probability 
to induce a continue rotation of the floxed DNA.  
Therefore, this system uses different pairs of Lox sites to determine an irreversible recombination, 
where the final product is an inversion of the floxed DNA. 
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3.  Inducible Cre 
 
A gene can act in different moments and different tissues; so, it is important to induce and modulate 
the gene expression with a spatial and temporal regulation.  
Indeed, restricting the expression of Cre to a time defined window by the experimenter avoids 
problems linked to the activation or inactivation of a gene early in development. On the other hand, 
tissue specific expression of Cre helps to study the role of a given gene selectively. 
The spatial regulation of Cre is possible with tissue-specific promoters that are used to drive the 
expression of Cre in the cell population or tissue of interest.  
The temporal regulation is possible in two ways. First, the use of a regulated promoter, such as the 
tetracycline-regulated promoter. In this case, there are two possible strategies, tet-ON and tet-OFF.  
In tet-OFF system, the gene expression is under the tetracycline-regulated promoter that is regulated 
by tetracycline-controlled transactivator (tTA). The expression is downregulated only with the 
administration of tetracycline or its derivatives (doxycycline), which bind the tTA, preventing its 
interaction with the promoter. The mutated system tet-ON works in opposite than tet-OFF, in which 
rtTA is not functional in the absence of tetracycline but requires the presence of the ligand for 
transactivation (Figure 7) [6]. 
 
 
Figure 7: Tet-OFF and Tet-ON system: A) Tet-off system, in which the administration of doxycycline (DOX) induces the 
downregulation of the transgene. B) Tet-on system, in which the administration of doxycycline induces the upregulation 
of the transgene. 
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The other way to achieve the temporal control, is the regulation of Cre activity with a small molecule 
inducer. In this case, Cre is fused to a Ligand-Binding-Domain (LBD) that prevents its nuclear 
translocation (Figure 8) [6], [9], [10]. 
 
Figure 8: Spatially and temporally regulation of Cre recombinase: on top, the plasmid with Cre-LBD (inducible Cre) 
under a tissue specific promoter (TSP). The HSP90 bind LBD, avoiding the genome recombination. With the 
administration of a drug (4-OHT) the LBD is free, allowing the genome recombination.   
 
In the beginning, LBDs were hormone-binding domains of nuclear receptor, such as the receptor for 
glucocorticoids, estrogens, or progesterone. To avoid activation of the Cre recombinase by 
endogenous ligands, the LBDs have been mutated in some points of nucleotide sequences. These new 
LBDs bind synthetic agonists (such as tamoxifen or its derivate 4-hydroxy-tamoxifen 4-OHT), but 
not the endogenous hormones. Therefore only the exogenous ligand introduced by researchers can 
activate Cre recombinase.  
Diverse hypothesis can explain the regulation of the protein fused with LBD, such as the bond of 
Hsp90 to it in the absence of steroid. Hsp90 (Heat Shock Protein 90) are cytoplasmic proteins 
involved in the Quality Control System of the cell. Hsp90 interacts with the LBD in the cytosol and 
thereby prevent the translocation of inducible Cre to the nucleus where DNA recombination occurs. 
The binding of the ligand is thought to produce conformational changes of the fusion protein and 
changes in the intracellular localization associated to the nuclear translocation [9]. 
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A large number of proteins were fused to the LBDs of various vertebrate steroid receptors: the 
estrogen (ER), glucocorticoid (GR), progesterone (PR), androgen (AR) and mineralocorticoid (MR) 
receptor.   
One of the more used LBD in vivo is ERT, an estrogen receptor mutated in some points in nucleotide 
sequence to response only to Tamoxifen. Indeed, the best commercially available Cre recombinase is 
flanked by two ERT2 (ERT2-Cre-ERT2, Addgene #13777) (Figure 9). 
 
 
 
 
Figure 9: Commercially available inducible Cre recombinase (ERT2-Cre-ERT2, Addgene #13777): Cre recombinase is 
fused with two ERT2 domains, one in N-terminal and one in C-terminal. 
  
Tamoxifen is an antagonist/agonist of ERT, with an affinity around 10 nM, that can pass through the 
blood-brain barrier. Following its administration, tamoxifen is metabolized and transformed in 
various active metabolites. One of them is 4-hydroxytamoxifen (4-OHT) that has a much higher 
affinity to ERT than Tamoxifen (approximately 10-fold more with the mutated ERT2). 
The Tamoxifen administration has some negative effects on the animal. Because of its antiestrogenic 
properties, it can bind the endogenous receptors to induce toxicity, inducing different processes. 
Therefore several studies have defined the concentration and the minimal number of doses for 
different systems. For example, in the brain the Tamoxifen administration is 1-2 mg twice a day for 
5 days [9]. These conditions are somewhat toxic for the organism, so it would be desirable to find a 
very sensitive system that responds efficiently with a low dose of Tamoxifen. 
 
 
 
 
 
 
 
 
 
 
Cre LBD LBD Prom Poly A 
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4.  Fluorescent Proteins 
 
Fluorescent proteins have a tertiary structure, organized as a capped β-barrel that serves as a shell to 
prevent chromophore quenching by solvent molecules (Figure 10). 
 
 
Figure 10: β-barrel structure of a fluorescent protein and chromophore formation reactions, in which there are three 
consecutive steps (cyclization, dehydration and oxidation) between three consecutive amino acid residues (Ser65–Tyr66–
Gly67). 
 
The β-barrel structure consisting of eleven β-strands, with an alpha helix containing the covalently 
bonded chromophore 4-(p-hydroxybenzylidene)imidazolidin-5-one (GFP).  
Fluorescent proteins maturation includes two steps: protein folding and chromophore formation 
(limiting step). The chromophore is generated after several autocatalytic reactions of internal amino 
acid residues and O2 without any cofactors or enzymes.  
The fluorescent proteins should have some properties [11]: 
1) Efficient expression without toxicity and enough brightness to have sufficient signal above 
autofluorenscence;  
2) Sufficient photostability during the experiment; 
3) Absence of oligomerization; 
4) Insensitivity to environmental effects that could confound quantitative interpretation of 
experimental results; 
5) Minimal crosstalk in their excitation and emission channels. 
The brightness of a fluorescent protein is determined by several variable factors, including the 
intrinsic brightness of the protein, the optical properties and camera sensitivity to the emission 
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spectrum. Brightness determines the sensitivity and signal to noise ratio for the fluorescence 
detection. 
The intrinsic brightness is determined by its maturation speed and efficiency, extinction coefficient 
(EC, capacity for light absorption at a specific wavelength), quantum yield (Φ or QY, the fraction of 
photons emitted per number of photons absorbed), and photostability. These properties change with 
the experimental condition: for example, in vivo the brightness is determined by a number of 
parameters such as cell type, expression efficiency, mRNA and protein stability, efficiency and rate 
of chromophore maturation, and the fusion protein partner [11]. Therefore it is important to choose the 
best brightness and expression depending on the living cell condition. The photostability is the 
measure of photobleaching, a process in which the fluorescent protein loses its brightness after being 
excited. All fluorescent proteins photobleach upon extended excitation with different rate. 
The wild-type fluorescent proteins are dimeric or tetrameric. The oligomerization causes a long 
maturation and the formation of aggregates of the fluorescent proteins. In vivo, the maturation rate 
and efficiency depend on oxygen concentration, temperature, expressing cell type, and fusion protein 
partners. The formation of aggregates induce toxicity in the living cell, such as Red Fluorescent 
Proteins (RFPs), possibly caused by electrostatic interaction between positively and negatively 
charged surfaces of the monomers [12]. 
In some studies, the fluorescent proteins have been engineered into monomers or tandem dimers [12]. 
The development of monomeric fluorescent protein opens the possibility to use different fusion 
proteins in single cell. In addition, it is possible to distinguish between different fluorophores with 
minimal crosstalk.  
The two fluorescent protein used in our sensor are GFP and mDsRed. 
GFP (Green Fluorescent Protein) was discovered by Shimomura et al. (1962) as a companion protein 
to aequorin, the famous chemiluminescent protein from Aequorea jellyfish. GFP is the most 
fluorescent protein used to labelling the protein in living cells. It is a monomeric protein with a small 
size (238 aa). 
mDsRed is a monomeric red fluorescent protein generated from DsRed (red fluorescent protein 
cloned from Discosoma coral) to remove several critical problems, including a slow and incomplete 
maturation and obligatory tetramerization. Although this fluorescent protein photobleaches more 
easily and brightness is lower than DsRed. mDsRed has minimal emission when excited at 
wavelengths optimal for GFP, so it is an optimal protein to combine with GFP in fluorescence imaging 
[12]. 
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5.  Two-photon microscopy 
 
Fluorescent proteins are widely used as genetically encoded fluorescent reporters in biomedical 
research. There are different fluorescent proteins, with fluorescence emissions from blue to far red. 
To analyze these proteins there are different approaches, such as one-photon microscopy or two-
photon microscopy. 
Two-photon excitation, first described by Maria Göppert-Mayer (1931), is a fluorescence process in 
which a fluorophore is excited by the simultaneous absorption of two photons. The probability of this 
event is σ2, two-photon absorption cross-section. 
One-photon fluorescence involves exciting a fluorophore from the electronic ground state (S0) to an 
excited state (S1) by a single photon. This process typically requires photons in the ultraviolet or 
blue/green spectral range. The same excitation process can be generated by the simultaneous 
absorption of two less energetic photons (typically in the infrared spectral range) under sufficiently 
intense laser illumination. This nonlinear process can occur if the sum of the energy of the two 
photons is greater than the energy gap between the molecule’s ground and excited states (Figure11). 
 
 
 
Figure 11: Comparison of one and two-photon fluorescence microscopy. On left, an image of two-photon and one photon 
fluorescence signal. In two-photon fluorescence microscopy, the fluorescence is confined to the focal point in contrast to 
one-photon microscopy, in which there is fluorescence around the focal point. On right, schematic representation of 
fluorophore electronic states. S0 is the electronic ground state and S1 is the excited state. In one-photon fluorescence, the 
excitation process requires photons in the ultraviolet or blue/green spectral range. In two-photon fluorescence, the same 
excitation process can be generated by the simultaneous absorption of two less energetic photons (typically in the infrared 
spectral range).  
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Since this process depends on the simultaneous absorption of two infrared photons, the probability of 
two-photon absorption by a fluorescent molecule is a quadratic function of the excitation radiance.  
To obtain a significant number of two-photon absorption events (in which both photons interact with 
the fluorophore at the same time), the photon density must be higher than the amount required to 
generate the same number of one-photon absorptions. Two-photon laser scanning microscopy 
(2PLSM) has the ultrafast (femtosecond or picosecond pulse widths) lasers with high repetition rate 
(80 MHz) to generate this phenomenon. The lasers have a higher peak power and a lower duty cycle, 
inducing a lower average power on the specimen but a high two-photon excitation efficiency. 
Two-photon microscopy offers significant advantages over one-photon microscopy for deep tissue 
imaging. Indeed, the advantages of two-photon excitation include reduced out-of-focus 
photobleaching, photodamage, less autofluorescence, deeper tissue penetration and intrinsically high 
three-dimensional resolution [13], [14]. 
In two-photon microscopy, the fluorescence signal can be confined to a region 1µm thick about the 
focal point in contrast to one photon microscopy, in which there is fluorescence around the focal point 
(Figure 11). Therefore, the one photon microscope uses the emission pinhole aperture to reject out-
of-focus light. Inside thick specimens, scattering of the fluorescent photons is inevitable. The resultant 
path deviation causes a significant loss of these photons at the confocal pinhole.  
To optimize two-photon excitation, it is important to know the two-photon absorption (2PA) spectra 
of the target protein, its quantum yield and the cross section [14]. 
The shape of the 2PA spectrum is different from the shape of the 1PA spectrum, because some vibronic 
transitions become enhanced in the two-photon process than one-photon process (Figure12). 
The most notable difference between the 2PA and 1PA spectra is the appearance of strong two-photon 
absorption in the region of shorter wavelengths, so that it is possible to excite simultaneously two 
proteins with very different Stokes shift. 
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Figure 12: Structure of the one and two photon absorption of a fluorescent protein. At the top, one-photon absorption 
(1PA, ε) spectra and two-photon absorption (2PA, σ2) spectra of TagRFP. At the bottom, Jablonsky diagram of 1PA and 
2PA transitions.  
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6. In vivo  
 
Gain of function and loss of function studies that use transgenic animals have greatly advance our 
understanding of the molecular and cellular mechanism of development and diseases.  
The mouse is the most used transgenic animal in research because it shares many genes with human. 
Mario R. Capecchi, Martin Evans, and Oliver Smithies created the first recorded knockout mouse in 
1989, for which they were awarded the 2007 Nobel Prize in Physiology and Medicine. 
Knock-out mutagenesis is the usual method in in vivo analysis of gene function with the use of 
specific genetic modifications [15]. 
There are two strategies to create transgenic animals for knock-out mutation. The first is the use of 
transgenesis, which consist of the introduction into the genome a transgene, a fusion gene containing 
a promoter sequence and a cDNA. The cDNA can contain a wild-type or a mutated gene of interest 
and it is introduced with a random recombination. The second is the use of gene targeting, which 
consist of the introduction of specific mutations into a gene of interest by homologous recombination 
using embryonic stem cells (ESC). ESC are derived from the inner cell mass of a mouse blastocyst 
and they maintain their totipotency under specific conditions. These cells can be mutated and 
transferred in an embryo mouse again, in which they participate in the development of whole 
organism, including germ lines, thereby transmitting their genotype to the next generation (Figure 
13). The use of a mouse line with a knock-out is limited to genes that are not involved in development 
or fundamental for the life cell, because the elimination of these genes is not compatible with life, 
and the animal dies. With this method, it is not possible to study the target gene in a single tissue, but 
all cells present the knock-out mutation. 
A possible solution is the introduction of a conditional mutation, that has wild-type (or less severe) 
phenotype under certain permissive environmental conditions and a mutant phenotype under certain 
restrictive conditions. In research, the induction of a knock-out mutation is possible with the use of a 
floxed animal with Cre recombinase. The system Cre/lox can make the excision of floxed gene, 
generating a knock-out mutation. When a Cre mouse (in which is expressed constitutive Cre 
recombinase) is crossed with a mouse that contains a floxed gene in its genome, the inactivation of 
the target gene may induce early embryonic death as in the classic knock-out mutation. However, the 
possibility to control Cre recombinase with an inducible promoter (Tetracycline-Inducible system) or 
an Inducible Cre recombinase allows to define the time and spatial window in which knock-out 
mutation can be occur. The Cre-LBD mouse lines express a tamoxifen-regulated Cre under a general 
or a cell-type-specific promoter. 
An easier strategy is to introduce a plasmid with inducible Cre in a floxed animal and then induce the 
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recombination in a specific temporal and spatial window. 
A powerful technique for the introduction of genes into organism is in vivo electroporation, in which 
it is possible to introduce more than two different DNA constructs into the same cells at once [10].  
 
 
 
 
Figure 13: A) Transgenic mouse; B) Knock-in or Knock-out mouse. 
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Material and Methods 
I. Cloning 
 
The cloning process includes several consecutive steps that allow the creation of a new 
construct from parental constructs.  
All our constructs are obtained with several steps (the following pipeline): 
- Digestion with restriction enzymes of vector and insert: use of appropriate restriction 
enzymes to generate desired fragments with compatible cohesive ends. All the process 
happens in a specific buffer that creates the optimal condition to the enzyme catalysis (2 
hours). 
- Electrophoresis: electrophoresis gel (Agarose 1%) to separate the fragments basing on 
their size and charge. Afterwards the specific gel bands for vector and insert are cut off. 
- Gel purification and extraction: use of Wizard SV Gel and PCR Clean Up System 
(Promega) kit. 
- Ligation of vector and insert: ratio is 1:5 (vector to insert) to promote the ligation between 
vector and insert and the ensuing circularization. The reaction is catalyzed by T4 DNA 
Ligase in T4 DNA Ligase buffer over-night at 16°C. 
- One Shot Chemically Competent E.Coli transformation (Stbl3 and TOP10): 
transformation with 5 µl DNA ligation and plating on selective medium over-night. 
- Pre-inoculation and Miniprep: selection of single colonies and growth in liquid medium 
(LB medium) with antibiotic (Ampicillin) for 12 hours. After, there is the plasmid DNA 
extraction with Wizard Plus SV Minipreps DNA Purification System kit (Promega). 
- Digestion of MINI: digestion of plasmids with opportune enzymes to obtain unique bands 
for the construct. These bands differentiate the new construct from the original. 
- Inoculation and Maxiprep: selection of positive colonies and inoculation in growth liquid 
medium with antibiotic over-night. Finally, the plasmid is extracted with extraction 
Plasmid Plus MAXI (Quiagen) kit and DNA title is quantified with a biophotometer. 
 
II. Transfection 
 
The transfection process is a set of methods by which DNA can be introduced in the eukaryotic cells.  
The cells acquire the exogenous DNA and it can be integrated or not in the genome.  
Different transfection methods are used, such as electroporation, lipofectamine and effectene. 
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II a. Electroporation:  
We used the Neon Transfection System (Invitrogen) kit: 
- Seed cells to 70-90% confluence. Wash the culture plate with PBS (without Ca2+ and 
Mg2+), trypsinize the cells using trypsin/EDTA and incubate at 37°C and 5% CO2 for at 
least 5 minutes. 
- Resuspension of the cells with DMEM (Dulbecco's Modified Eagle Medium), transfer to 
a 1.5 ml microcentrifuge or a 15 ml conical tube and centrifugate the cells at 200 x g for 
5 minutes at room temperature. 
- Aspirate the medium and wash cells with PBS by centrifugation at 200 x g for 5 minutes 
at room temperature. 
- Take an aliquot the cell suspension and count cells to determine the cell density 
- Aspirate the PBS and resuspend the cell pellet in Resuspension Buffer R at a specific final 
density depending on the type and cell density. Gently pipette the cells to obtain an 
homogenous single cell suspension. 
- Set up the Neon Tube with 3 ml Electrolytic Buffer (use Buffer E for 10µl Neon Tip and 
Buffer E2 for 100 µl Neon Tip) into Neon Pipette Station. 
- Set the desired pulse condition (voltage, width and pulse) based on your cell type. 
- Add cells to the tube containing plasmid DNA and gently mix. There is a specific table 
for cell concentration, DNA, and plating volumes to use for specific cell types. 
- Take the cells and DNA mix with a Neon Tip and insert it into Neon Pipette. Start the 
electroporation.  
- Transfer the samples into prepared culture plate containing medium and incubate at 37°C 
and 5%. 
 
II b. Lipofectamine 
We used the Lipofectamine 3000 Reagent kit (Invitrogen): 
- Seed cells to 70-90% confluence. 
- Diluition of Lipofectamine 3000 Reagent in Opti-MEM Medium (ratio 3:5). 
- Prepare the mixture of DNA (0.5 - 5µg/µl) with Opti-MEM Medium (ratio 1:5) and P3000 
Reagent (2µl/µg DNA). 
- Add diluted DNA to diluted Lipofectamine (ratio 1:1) and incubate at room temperature 
for 5 minutes. 
- Add the mixture to cells and incubate at 37°C and 5% CO2 
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II c. Effectene 
We used the Effectene Transfection Reagent kit (Quiagen): 
- Seed cells 70-90% confluence. 
- Add Enhancer to DNA (ratio 1:8 of DNA to Enhancer, with different amounts depending 
on the plate and so on the number of cells) and mix by vortexing for 1s. 
- Incubate at room temperature for 5 minutes, and then centrifuge briefly to remove drops 
from the top of the tube. 
- Add Effectene Transfection Reagent to the mixture, mix by vortexing for 10 s and incubate 
at room temperature for 10 minutes. 
- Wash cells with PBS and add a part of growth medium.  
- Add growth medium to mixture, mix by pipetting and add the mixture to the cells. 
- Incubate the cells at 37°C and 5% CO2. 
 
III. Cell Culture 
 
The plasmid are transfected in different cell cultures (cell line HEK 293T, NIH 3T3 and primary cell 
Fibroblasts, Astrocytes, Cardiomyocytes). 
Cell line HEK 293 T (Human Embryonic Kidney) and NIH 3T3 (3-day transfer, inoculum 3 x 105 
cells, fibroblasts) are incubated at 37°C with 5% CO2. The growth medium is DMEM (Dulbecco’s 
Modified Eagle’s Medium) with a low glucose concentration (1000 mg/mL), FBS 10% (Fetal Bovine 
Serum), streptomycin and penicillin (1%), not essential amino acids (1%), sodium pyruvate (1%). 
The medium has to be change every 3 days. 
Cells are manipulated in sterile conditions under a tissue culture hood. It is a carefully enclosed bench 
designed to prevent contamination of semiconductor wafers, biological samples, or any particle 
sensitive materials 
 
Tamoxifen treatment 
 
Cell cultures were treated with 4-hydroxytamoxifen (4OHT), dissolved in ethanol. The aliquot is 1 
mM and Tamoxifen is diluted in 2 ml of culture medium to obtain a final concentration of 1-2 µM. 
After one day, Tamoxifen is removed and new culture medium is added. 
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IV. In utero electroporation 
In vivo experiments were performed on wild-type (CD1 o C57BL/6) or floxed (MeCP2) mice. 
Mice were transfected by means of the in utero electroporation technic. The protocol allows the 
delivery of multiple plasmids in population of neurons [16], [17]. The tripolar configuration is based on 
the use of three electrodes, localizing the plasmids in a specific area. The use of three electrodes 
allows easy transfection of various brain areas, including the hippocampus, visual cortex, motor 
cortex, prefrontal cortex, and cerebellum. 
The electric shocks destabilize the structure of the cell membrane and induce the formation of 
transient electropores. Therefore, negatively charged DNA drifts towards the anode in the electric 
field, actively penetrating into the cell cytoplasm and allowing transfection.  
Three electrodes generate a symmetrical electrical field, which allows bilateral electroporation of the 
brain hemispheres by a single electroporation episode (see Figure 14).  
The position of the third electrode defines the electroporated region (0° for hippocampus and motor 
cortex, 90° for visual cortex to the horizontal plane). The orientation of electric fields and the DNA 
direction is defined by polarity of electrodes. If the forceps-type electrodes are connected to positive 
pole (+) or negative pole (-), the third electrode is connected to opposite pole. The limits is the 
complication of the tool. Furthermore, it is necessary the presence of two operators.  
 
 
 
Figure 14: Three-electrode configuration: a) Schematic representation of the utero electroporation procedure with three-
electrode. b) Images of the utero electroporation. c) 3D representation of the multi-electrode device. 
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The plasmids have to be diluted in sterile water to their final concentration (1-4 µg/µl) and Fast Green 
is added dye (0.3 mg/ml) to enable visualization of the injected site. The maximum final volume of 
DNA is 80 µl. This volume is sufficient to electroporate 15 embryos from a single mother. 
The entire procedure is carried on in sterile conditions and with all precautions for the operators.  
To anesthetize the animal it was used appropriate levels of isoflurane (4.0%) and oxygen (1.5 
ml/min). A painkiller and an antibiotic were injected intramuscularly into the hind paws. 
The mother is sterilized in the area of surgery. The cut is in the abdomen to permit the exposition of 
the uterus. The DNA was loaded into a microinjection capillary without the presence of bubbles and 
it was injected into one of the brain’s lateral ventricle. The injection of DNA is complete when the 
whole ventricle is full and the Fast Green dye is clearly visible. At this point, the fetus is 
electroporated with specific parameters.  
In the end, the embryos are introduced again in the mother’s abdominal cavity to continue the 
pregnancy. 
 
In vivo imaging 
 
In our work we used two-photon microscopy for in vivo imaging, which allows to obtain images from 
transfected animals. 
Mice were anesthetized with an intraperitoneal injection of urethane 20%, obtained with 1 g of 
urethane diluted in 5 ml of NaCl 0,9% solution. In addition, it was used a local anesthetic (lidocaine) 
to avoid excessive pain during the cut and the incision of the skin. ACSF (Artificial CerebroSpinal 
Fluid) was used to keep hydrated the surgical area and to facilitate the removal of connective tissue. 
To create a cranial window (2,5-1 cm diameter) it was used a micro drill and on top was laid a sterile 
glass with the same diameter. On the craniotomy was fixed a metal bar with Paladur, which is used 
for head fixation, to immobilized the mice under the objective of a two-photon microscope, allowing 
the acquisition. 
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ACQUISITION AND DATA ANALYSIS 
 
Cell culture acquisition 
 
Cell were imaged at the two-photon microscope (Praire Techonologies) 4/5 days after transfection 
with an Olympus FL LUMPlan N 20x, 1.2NA water-immersion microscope objective. 
This system utilizes a Titanium:Sapphire (Ti:Sa) oscillator (Chameleon ùultra II, Coherent) that 
produces light from 700 nm at 1080 nm. 
The excitation power was measured by a power-meter 13PEM001 (Melles Griot) and regulated by a 
Pockels cell (302 Conoptics). 
The signal was separated from the excitation light and spectrally split into two PMT 
(PhotonMultipleier Tubes) channels for multicolor detection. The range of the channels are 490-560 
nm for the green channel and 584-630 nm for the red channel.  
Every acquisition was made with specific parameters to obtain the best images of the cell cultures 
without fluorescence saturation: 
- The excitation power at the sample was approximately 3,5 mW or 25 mW (depends on 
the cell types acquired); 
- The PMT voltage of both channels was 667 V; 
- The excitation wavelength was 950 nm; 
-  Images were acquired at the resolution of 512x512 pixel. 
Each group of samples has been acquired with in equivalent conditions in order to compare the 
different samples. 
 
In vivo acquisition 
 
During in vivo imaging experiments, images are acquired every 2 µm with (of) a Z stacks of 200-300 
µm of depth.  
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Data Analysis 
 
The acquired images were analyzed with ImageJ software and Origin Pro8 software. 
Our data analysis have the purpose to obtain quantitative results, to determine the degree of 
recombination of each cell which is deduced by its colorimetric analysis. Each image is analyzed by 
measuring the average fluorescence of every cell in the red and green channels. In the plot the X axis 
represents the average green fluorescence and the Y axis represents the average red fluorescence 
(Figure 15).   
 
 
Figure 15: Example of a scatter plot of neurons in vivo. On the left, the plot shows average green fluorescence on the X 
axis and avarage red fluorescence on the Y axis. On the right, the plot shows polar angle on the X axis and relative 
frequency on the Y axis. The animal is a postnatal day 25 (P25) mouse transfected with Beatrix 4.0 + ERT2-Cre-ERT2 
(ratio 500:1). 
 
In this plot is possible to deduce the trend and the distribution of the cells. In Figure 15 the cells trend 
to stay in two lines nearly the two axes. The cells change in the fluorescence intensity in the same 
axis because of the different numbers of plasmids in each cell.  
An important measure that can be deduced from these plot is the polar angle of each cell. The vector, 
that connects the single cell to the axes origin point, defines an angle with the X axis which is a 
measure of  the relative intensity of the green and red channels for each cell. 
The relative frequencies of the polar angles θ of each cell show the clear-cut segregation of the two 
fluorescent populations. The red fluorenscent population is to the left of the plot with low polar angle 
values, instead the green fluorescent population is to the right of the plot with high polar angle values.  
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RESULTS 
 
1.  Beatrix, the Sensor 
 
Beatrix is a plasmid that can create and reveal an expression mosaic, thus allowing to study the cell 
autonomous effects of a mutation in living cells and in vivo. There are different versions of this 
construct, each one being an optimization of the previous construct. 
The plasmid version that is used in this work is Beatrix 4.0 (B4.0). It is composed by three DNA 
sequences that express different proteins. Two of them express two different fluorescent proteins, red 
(DsRed) and green (GFP). The third sequence expresses Cre recombinase. The arrangement of the 
three DNA sequences allows to identify recombined cells (green cells) and not recombined cells (red 
cells).  
As shown in the Figure 16, Beatrix contains a red fluorescent protein in sense, a green fluorescent 
protein and a Cre recombinase in antisense under an ubiquitous CAG promoter. 
The CAG promoter is a strong synthetic promoter frequently used to drive high levels of gene 
expression in mammalian cells. 
CAG promoter was constructed in the lab of Dr Jun-ichi Miyazaki and it is composed by: 
- C : Cytomegalovirus (CMV) early enhancer element; 
- A : promoter, first exon and first intron of chicken β-actin gene; 
- G : splice acceptor of the rabbit β-globin gene.   
 
a. Before recombination 
 
 
b. After recombination 
 
 
Figure 16: A diagram of Beatrix 4.0: a) Before recombination, the plasmid is formed by a red fluorescent protein (DsRed) 
in sense, a green fluorescent protein (GFP) and the Cre recombinase in anti-sense. The whole coding region is flanked by 
two different pairs of Lox sites. b) After recombination, the plasmid presents GFP and Cre recombinase in sense, and the 
DsRed in antisense. The coding region is flanked by only two different Lox sites. 
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Two different pairs of Lox sites flank the DNA sequences as in the Flex Switch system. 
Therefore, before recombination, the sensor expresses only the red fluorescent protein, but after 
recombination, it expresses both green fluorescent protein and Cre recombinase (Figure 16). 
The expression of a single fluorescent protein at a time excludes the possibility of the other protein 
expression. 
Our construct includes the Cre recombinase gene to generate a saturating Cre activity in each cell, 
where the induction of the sensor occurs with a low level of Cre activity. This situation allows to 
avoid false positives and false negatives. 
False positives are cells that express the green fluorescent protein but the genome is not recombined.  
False negatives are cells that express the red fluorescent protein but the genome is recombined. 
When a single Beatrix plasmid is recombined, it starts expressing Cre recombinase, which amplifies 
the original triggering recombination, thus recruiting more plasmids. Therefore, in each cell there is 
an amplification and a saturation of Cre activity.  
In this condition, we are sure that in each green cell all the plasmids are recombined and the genome 
is excised, avoiding the presence of yellow cells (Figure 17). Yellow cells are uncertain situations, in 
which both red and green fluorescent protein are expressed due to recombined and not recombined 
plasmids in the same cell. In this situation, it is not possible to assume that the genome is recombined 
(Figure 17). 
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Figure 17: Two different Beatrix: A) Beatrix 2.0 without amplification: a subsaturating pulse of Cre activity cannot 
recombine all plasmids and the genome. B) Beatrix 4.0 with amplification: a subsaturating Cre activity can recombine 
one or few more plasmids that express Cre recombinase. Therefore, each cell presents an amplified saturating Cre activity 
that leads to the recombination of all plasmids and of the genome. 
 
 
In the mosaic, the presence of false negatives and false positives is possible with a low level of Cre 
activity, an essential situation to obtain only a few recombined cells for the in vivo studies.  
Therefore, in our experiments we used subsaturating level of constitutive Cre recombinase or a low-
level activation of inducible Cre to create a genetic inactivation mosaicism. 
Beatrix 4.0 has been inserted in two different scaffolds: B4.0 in 13777 and B4.0 in pCAG Cepko-
MCS. 
Addgene #13777 is the plasmid pCAG ERT2-Cre-ERT2, the commercial available inducible Cre, 
instead pCAG Cepko-MCS is a plasmid obtained from the cloning of Addgene #13777 (Spe HF + 
EcoRI ) and pCAG-MCS (Nhe HF + EcoRI). 
In the construct B4.0 in 13777, in the Addgene plasmid #13777 the coding sequence of ERT2-Cre-
ERT2 has been replace by Beatrix 4.0, instead in B4.0 in pCAG Cepko-MCS, the Beatrix 4.0 sequence 
has been cloned in the MCS of pCAG Cepko-MCS, obtained from the cloning of B4.0 in 13777 and 
pCAG-MCS (XmaI + XhoI). 
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 A previous construct is Beatrix 2.0 (B2.0), composed only by the two fluorescent proteins in opposite 
orientation (Figure 18). 
a. Before recombination 
 
b. After recombination 
 
 
Figure 18: Beatrix 2.0: Before recombination, the construct expresses the red fluorescent protein (DsRed), while after 
recombination it expresses the green fluorescent protein (GFP). 
 
This construct does not include the Cre recombinase gene, so it is not characterized by amplification, 
generating false negatives and false positives with low constitutive Cre or inducible Cre activity. 
Indeed, it produces yellow cells due to the presence of both red and green fluorescent proteins in the 
same cell.  
A comparable construct is Beatrix 4.0 noEX2 (B4.0 noEX2), in which the exon 2 of Cre recombinase 
is removed. The exon 2 of Cre harbors the catalytic domain, so this construct has no Cre-amplification 
as for Beatrix 2.0.  
The generation of Beatrix 4.0 noEX2 is obtained by the cloning Beatrix 4.0 and B4.0 EX1 (AgeI HF 
+ XhoI). In this cloning, the coding sequence of Cre recombinase present in Beatrix 4.0 has been 
replaced by the coding sequence of Cre recombinase of B4.0 EX1. 
 
Cell cultures  
 
Beatrix 4.0, Beatrix 4.0 noEX2 and Beatrix 2.0 were transfected in cell cultures (HEK and NIH) to 
characterize theirs behavior in the presence of constitutive Cre.  As described in the Materials and 
Methods section (Data Analysis and Fig.15), our data analysis have the purpose to obtain quantitative 
results, to determine the degree of recombination of each cell which is deduced by its colorimetric 
analysis. Each image is analyzed by measuring the average fluorescence of every cell in the red and 
green channels. The first step is the creation of a scatter plot of the red (X axis) and green (Y axis) 
fluorescences. In this plot is possible to deduce the distribution of the cells and the possible presence 
of yellow cells.  
An important measure that can be computed from the plot is the polar angle. The relative frequencies 
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of the polar angles θ of each cell show the clear-cut segregation of the two fluorescent populations. 
The red fluorenscent population is to the left of the plot with low polar angle values, instead the green 
fluorescent population is to the right on the plot with high polar angle values (Figure 19).  
 
 
Figure 19: Comparison between B4.0 noEX2 (on top) and B4.0 (on bottom) with constitutive Cre (ratio 500:1) in HEK 
cell cultures: in B4.0 noEX2 there are 95% of not recombined red cells, instead in B4.0 there are 71,3% of not recombined 
cells. The cell cultures are acquired 4dd after the transfection. Every condition is represented with a scatter plot (on the 
left), in which each point represents a cell (the two axes are in the logarithmic scale with red fluorescence on X axis and 
green fluorescence on Y axis), and a plot (on the right) with the relative frequencies of polar angles. 
 
In Figure 19, it is possible to see and compare the distribution of the fluorescent cells of Beatrix 4.0 
and Beatrix 4.0 noEX2. B4.0 noEX2 shows a high relative frequency in two bins with lower polar 
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angle values, suggesting that many cells have a high red fluorescence (95% of cells characterize the 
bins associated to red fluorescence). Instead, B4.0 shows a lower relative frequency in the two bins 
(the same of B4.0 noEX2) and the presence of bins with high polar angle values. Therefore, in the 
same experimental condition B4.0 leads to more green (fully recombined) cells than B4.0 noEX2. 
These date are consistent with the amplificatory effect of the Cre gene included in B4.0. These 
experiments were replicated in a different cell culture, NIH 3T3 (Figure 20-21). 
 
Figure 20: NIH cell cultures transfected with B4.0 noEX2 + constitutive Cre (ratio 500:1): the plots are the results of two 
different experiments. There are 81,1% of not recombined cells. 
 
 
Figure 21: NIH cell cultures transfected with B4.0 + constitutive Cre (ratio 500:1): the plots are the results of two different 
experiments. There are 49,3% of not recombined cells. 
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In the scatter plot of Figure 21 is possible to observe and distinguish the two populations. The 
amplification is more visible in NIH than in HEK, maybe because of the differences on the expression, 
maturation and degradation protein levels in the two cell types. In NIH with B4.0 there are high 
relative frequencies in bins with great polar angle values, corresponding to green cells. Furthermore, 
the yellow cells are fewer than in HEK cell cultures. 
Instead, in the case of B4.0 noEX2 there are no significant differences. 
 
Beatrix 2.0 and Beatrix 4.0 transfected with the commercially available inducible Cre (Addgene 
#13777), after the administration of a single pulse of Tamoxifen present different answers. 
In the case of Beatrix 2.0 (Figure 22), it is possible to observe many red cells (90,5%). 
 
 
Figure 22: HEK cell cultures trasnfected with Beatrix 2.0 + ERT2-Cre-ERT2 (ratio 50:1) after a single pulse of Tamoxifen. 
90,5% of cells are not recombined.   
 
In the same conditions of Beatrix 2.0, Beatrix 4.0 presents more green cells than red cells (only 17,6% 
of not recombined cells) (Figure 23). 
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Figure 23: HEK cell cultures with Beatrix 4.0 + ERT2-Cre-ERT2 (ratio 50:1) after one pulse of Tamoxifen. 17,6% of cells 
are not recombined. 
 
The comparison of these two figures suggests that, thanks to the presence of Cre recombinase into 
the construct, Beatrix 4.0 is more sensitive to Tamoxifen induction than Beatrix 2.0. Indeed, a single 
pulse with a low concentration of tamoxifen is sufficient to induce recombination almost in all cells.  
This finding allows to reduce significantly the Tamoxifen dosage, which is beneficil, since Tamoxifen 
is toxic for the cells and the animals. 
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2. A novel Inducible Cre 
 
As we saw, the temporal regulation of Cre activity is possible by using an Inducible Cre that can be 
activated in a specific temporal window after the administration of Tamoxifen.    
In cell cultures, this tool shows leakage: a low level of Cre activity is detected even without the drug 
(Figure 24). There are many different hypothesis to explain leakage, such as the saturation of HSP90.  
 
 
 
                                                                          
Figure 24: HEK cell cultures with Beatrix 4.0: on top, B4.0 alone (100% red cells). On bottom, B4.0 with ERT2-Cre-
ERT2 not treated (ratio 50:1): there are some green cells (arrows in the image). 99,5% of the cells are red. The cell cultures 
acquisition is 4 dd after the transfection, so the recombination rate is k=0,13% per day.  
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The Figure 24 shows the sensitivity of Beatrix 4.0 to the leakage of inducible Cre, in which 4 days 
after the transfection the rate of recombination is only 0.13% per day.  
The recombination induced by our construct can be compare with radioactive decay. The event is 
entirely random and it is impossible to predict when occurs. However, it is equally likely to recombine 
at any instant in time. Furthermore, the reaction is irreversible. Therefore, to measure the 
recombination rate is used the radiation decay formula: Pt = P0 * e kt (Pt is the recombination 
probability at the time t, P0 is the recombination probability at the time 0 and k is a decay constant).  
 
The different versions of Beatrix were transfected with constitutive or inducible Cre in vivo mice with 
the in utero electroporation procedure. The transfection  was performed by our collaborators in 
Genova (Dr. Laura Cancedda) and the following in vivo imaging was performed and analyzed by us 
(Figure 25). 
 
 
Figure 25: In vivo imaging of the mouse occipital cortex (postnatal day p25) with Beatrix 4.0 + Constitutive Cre (ratio 
500:1). There are 77% of recombined cells. 
 
The image in Figure 25 has been acquired from the mouse occipital cortex (p25) after in utero 
transfection with B4.0 and constitutive Cre. It is possible to see red and green cells (77% of 
recombined cells). 
Our purpose is to reduce the leakage in order to ensure an accurate control of Cre activity. Therefore, 
we are exploring different strategies to reduce the effects of the leakage of inducible Cre.  
In this line, we explored two different strategies by acting on protein stability or/and mRNA stability 
(Figure 26). Both strategies leads to a decrease of Cre cytoplasmic concentration, decreasing the 
probability of nuclear translocation in absence of Tamoxifen.  A possible hypothesis it is the not 
saturation of HSP90s, that can bind and induce the cytoplasmic localization of all inducible Cre. 
In the beginning, we fused a destabilized domain (DD) to the N-terminal of ERT2-Cre-ERT2 (Addgene 
#13777).  
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From this construct, we cloned other plasmids to analyze the differences of leakage and to define the 
best version. Figure 26 shows a schematic representation of the different versions of inducible Cre 
that we have generated. 
 
 
Figure 26: Three different new inducible Cre with DD in the N-terminal: A) DDERT2-Cre-ERT2; B) DDERT2-Cre; C) 
DDCre-ERT2. 
 
DD is a mutant destabilizing form of bacterial dihydrofolate reductase (ecDHFR), which is degraded 
through the proteasome 26S pathway [18]. The degradation can be blocked with the ligand 
Trimethoprim (TMP). TMP-inducible protein stabilization is particularly attractive for in vivo 
applications because TMP can be easily delivered to laboratory animals, penetrates the blood-brain 
barrier and does not have endogenous targets in mammals [18].  
The versions of new inducible Cre are obtained from different cloning: 
- DDERT2-Cre-ERT2 in 13777 from the cloning of Sigma DDERT2-Cre-ERT2 and Addgene 
#13777 (EcoRI + NotI); 
- DDERT2-Cre in 13777 from the cloning of Sigma DDERT2-Cre-ERT2 and #13777 (EcoRI 
+ XhoI); 
- DDCre-ERT2 in 13777 from the cloning of DDERT2-Cre-ERT2 in Addgene #13777 
(AscI). 
 
Cell cultures 
 
These plasmids were transfected with Beatrix 4.0 in HEK 293T cell cultures to induce mosaicism.  
When Beatrix 4.0 is transfected with one of the different inducible Cre, the cells cultures present 
leakage with different percentage of recombined cells. The images in Figure 27 show HEK cell 
cultures transfected with electroporation. Both plots show the relatively frequency fluorescence polar 
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angle. After 5 days by transfection, Beatrix 4.0 and ERT2-Cre-ERT2 shows 25,3% of leakage, whereas 
Beatrix 4.0 and DDERT2-Cre-ERT2 shows 10,7% of leakage.    
          
   
Figure 27: HEK cell cultures transfected with Beatrix 4.0 and an inducible Cre. On top Beatrix 4.0 + ERT2-Cre- ERT2 
(ratio 1:1) without treatment: the leakage is 25,3% and the recombination rate is 5,83% per day. On bottom Beatrix 4.0 + 
DDERT2-Cre-ERT2 (ratio 1:1): the leakage is 10,7% and the recombination rate is 2,26% per day. Acquisitions were 
performed 5 days after transfection. 
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Since leakage is still present with this batch of inducible Cre, we decided to decrease the mRNA 
stability by removing the entire PolyA sequence. 
 
 
 
Figure 28: Schematic representation of ERT2-Cre- ERT2 without PolyA. 
 
When Beatrix 4.0 is transfected with the wild-type inducible Cre without PolyA, the cell cultures 
show a decrement of leakage as shown in Figure 29. 
 
 
 
Figure 29: HEK cell cultures with Beatrix 4.0 + ERT2-Cre-ERT2 no PolyA (ratio 1:1): in the image is possible to see few 
green cells. The leakage is 4,5% and not recombined cells are 95,5%. The recombination rate is 0,92% per day. 
 
The lack of PolyA compromises mRNA stability, inducing a strong reduction of Cre concentration 
and thus of the overall leakage. The mRNA instability enhances mRNA degradation leading to a low 
cytoplasmic level of the protein. However, this is not yet sufficient to completely abolish leakage, as 
shown by the presence of green cells.  
To decrease further leakage, in addition, we generated an inducible Cre with both modifications, DD 
and the lack of PolyA (Figure 30). 
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Figure 30: Schematic representation of DDERT2-Cre-ERT2 without PolyA. 
 
When Beatrix 4.0 is transfected with DDERT2-Cre-ERT2 without PolyA, the cell cultures present few 
green cells. The leakage is 3,6% as the leakage only without PolyA (4,5%) (Figure 31). 
 
 
Figure 31: HEK cell cultures with Beatrix 4.0 + DDERT2-Cre-ERT2 no PolyA (ratio 1:1): in the image, there are few 
green cells. The leakage is 3,6% and there are 96,4% of not recombined cells. The recombination rate is 0,73% per day. 
 
This data analysis demonstrate that the alteration of Cre concentration is a possible way to decrease 
the leakage, but it is not completely abolishes it.  
There are different modifications that can be used to decrease the leakage. For example, it should be 
possible to work on 3’-5’UTR, splicing, cap5’and promoter. 
Alteration on transcription, such as on PolyA, could to create a Cre recombinase with lower selectivity 
for the LoxP sequences, thus leading to recombination of sequences different to the Lox sites. Sure 
enough, during transcription there are different important processes to determine the correct 
maturation of RNA. PolyA is a 3’UTR sequence involved on splicing, cytoplasmic translocation, 
protection by exonuclease activity, and on the correct end of translation. Therefore, the maturation is 
compromised, creating a protein which can be defective. 
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However, the lack of PolyA does not impair in functionality of the construct (Figure 32). 
 
 
Figure 32: HEK cell cultures with B4.0 + ERT2-Cre-ERT2 noPolyA. On top, B4.0 + ERT2-Cre-ERT2 noPolyA, in which 
most cells are red (95,1%) and the recombination rate is 1% per day. On bottom, B4.0 + ERT2-Cre-ERT2 noPolyA with 
Tamoxifen treatment, in which most cells are green (only 7,6% of not recombined cells). 
 
After the activation of inducible Cre by the administration of Tamoxifen, the recombination of at least 
one Beatrix permits the complete recombination of all plasmid in each cell. 
The use of a weak promoter could solve the problem, but it does not guarantee the same results in 
every cell types. The cell expression is not the same in different cell types, so the use of a weak 
promoter is not the solution. Therefore we decided to focus on protein stability, in order to impact as 
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little as possible on the Cre integrity. 
However, it is important to keep in mind that the status of genome, the promoter and the Cre 
expression levels influence the level of leakage.  
 
 
Split Cre 
 
The modifications of inducible Cre that we have shown were not sufficient to abolish the leakage, 
therefore, we are designing a new tool. 
The new tool is obtained by breaking ERT2-Cre-ERT2 in two fragments. 
Some groups [19], [20] have generated different systems in which the recombination of LoxP-flanked 
DNA sequences depends on the simultaneous activity of two promoters, that express the two 
fragments of Cre. Each fragment was fused to complementary domains to reconstitute recombinase 
activity.  
We decided to use the break points used in these studies [19] to break the inducible Cre into two 
fragments, coding for amino acids residues 19-59 / 60-343 aa and 19-104 / 106-343 aa. 
However, we do not separate the two fragments in two different plasmids but we will use P2A or 
IRES to separate the products of translation. 
P2A is a DNA sequence that allows the simultaneous expression of two proteins under a unique 
promoter. It is placed between the two coding protein sequences and, after translation, it breaks itself 
to generate the single proteins.  
IRES (Internal Ribosome Entry Site) is a biding DNA sequence for ribosome to start the translation. 
As P2A, it is between the two coding protein sequences but the two proteins are expressed separately.  
This possible tool is a future project and our hypothesis is that the break of inducible Cre will allow 
the complete elimination of the leakage. 
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Conclusion 
 
The sensor-inducer system proposed in this work can create and reveal mosaicism and cell-
autonomous effects in floxed cell cultures and in vivo. 
The improved version of our sensor, Beatrix 4.0, can distinguish, with two different fluorescence 
proteins, the healthy cells (red fluorescence) and the diseased cells (green fluorescence). In addition, 
the structure ensures that the switching of cell fluorescence is correlated to the recombination event, 
not only of all plasmids but also of the genome. This happens because of the presence of Cre 
recombinase in the construct. Its expression, after recombination, creates an amplification and 
saturation of Cre activity into the cell. Therefore, the probability of the recombination of all plasmids 
without affecting genome is very low. 
The spatial and temporal control of the tool is achieved through the association of an inducible Cre. 
Inducible Cre allows to regulate the percentage of mosaicism and to assess cell autonomous effects. 
During this work, we observed that Beatrix 4.0 is very sensitive to very low amount of Cre 
recombinase, and enhances the leakage of inducible Cre. Therefore, there is the need to create an 
inducer with lower leakage than the commercially available inducible Cre (ERT2-Cre-ERT2). 
We created and analyzed different versions of inducible Cre, working on protein and mRNA stability. 
This led to a reduction of the leakage from 25% of recombined cells after 5 days to less than 4%. Our 
finding suggest that the lack of PolyA has a stronger action on leakage than the presence of DD. 
The residual leakage on these constructs suggests that more work is required to achieve the complete 
absence of leakage.  The future perspective is to break the inducible Cre in two inactive fragments to 
further decrease the probability of Cre to recombine: the reaction will become possible only with the 
contemporary connection of the two fragments on the DNA. 
The final goal is to validate our system in different floxed primary mouse cultures, such as astrocytes, 
cardiomyocytes and fibroblast, with different floxed genes in order to generalize our system and to 
show its efficiency in all cell types, in living cells an in vivo.   
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